# Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

> **NCT00002098** · PHASE1 · COMPLETED · sponsor: **AJI Pharma USA** · enrollment: 50 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Lentinan
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00002098
- **Lead sponsor:** AJI Pharma USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 50 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002098, "Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*